Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

204 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
EGFRvIII upregulates DNA mismatch repair resulting in increased temozolomide sensitivity of MGMT promoter methylated glioblastoma.
Struve N, Binder ZA, Stead LF, Brend T, Bagley SJ, Faulkner C, Ott L, Müller-Goebel J, Weik AS, Hoffer K, Krug L, Rieckmann T, Bußmann L, Henze M, Morrissette JJD, Kurian KM, Schüller U, Petersen C, Rothkamm K, O Rourke DM, Short SC, Kriegs M. Struve N, et al. Among authors: faulkner c. Oncogene. 2020 Apr;39(15):3041-3055. doi: 10.1038/s41388-020-1208-5. Epub 2020 Feb 17. Oncogene. 2020. PMID: 32066879 Free PMC article.
Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide.
McAleenan A, Kelly C, Spiga F, Kernohan A, Cheng HY, Dawson S, Schmidt L, Robinson T, Brandner S, Faulkner CL, Wragg C, Jefferies S, Howell A, Vale L, Higgins JPT, Kurian KM. McAleenan A, et al. Among authors: faulkner cl. Cochrane Database Syst Rev. 2021 Mar 12;3(3):CD013316. doi: 10.1002/14651858.CD013316.pub2. Cochrane Database Syst Rev. 2021. PMID: 33710615 Free PMC article.
MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Systematic Review.
Brandner S, McAleenan A, Kelly C, Spiga F, Cheng HY, Dawson S, Schmidt L, Faulkner CL, Wragg C, Jefferies S, Higgins JPT, Kurian KM. Brandner S, et al. Among authors: faulkner cl. Neuro Oncol. 2021 Sep 1;23(9):1457-1469. doi: 10.1093/neuonc/noab105. Neuro Oncol. 2021. PMID: 34467991 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 33942105
EGFR and EGFRvIII analysis in glioblastoma as therapeutic biomarkers.
Faulkner C, Palmer A, Williams H, Wragg C, Haynes HR, White P, DeSouza RM, Williams M, Hopkins K, Kurian KM. Faulkner C, et al. Br J Neurosurg. 2015 Feb;29(1):23-29. doi: 10.3109/02688697.2014.950631. Epub 2014 Aug 20. Br J Neurosurg. 2015. PMID: 25141189
Diagnostic accuracy of 1p/19q codeletion tests in oligodendroglioma: A comprehensive meta-analysis based on a Cochrane systematic review.
Brandner S, McAleenan A, Jones HE, Kernohan A, Robinson T, Schmidt L, Dawson S, Kelly C, Leal ES, Faulkner CL, Palmer A, Wragg C, Jefferies S, Vale L, Higgins JPT, Kurian KM. Brandner S, et al. Among authors: faulkner cl. Neuropathol Appl Neurobiol. 2022 Jun;48(4):e12790. doi: 10.1111/nan.12790. Epub 2022 Mar 3. Neuropathol Appl Neurobiol. 2022. PMID: 34958131 Free PMC article. Review.
Diagnostic test accuracy and cost-effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma.
McAleenan A, Jones HE, Kernohan A, Robinson T, Schmidt L, Dawson S, Kelly C, Spencer Leal E, Faulkner CL, Palmer A, Wragg C, Jefferies S, Brandner S, Vale L, Higgins JP, Kurian KM. McAleenan A, et al. Among authors: faulkner cl. Cochrane Database Syst Rev. 2022 Mar 2;3(3):CD013387. doi: 10.1002/14651858.CD013387.pub2. Cochrane Database Syst Rev. 2022. PMID: 35233774 Free PMC article. Review.
204 results